stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) Revenue growth
Haemonetics Corporation's revenue growth over the twelve months to 30 September 2026 was 4.11%, up 6.1 percentage points from fiscal 2026 (−1.97%). Over the past ten years it has ranged from −11.9% (fiscal 2021) to 17.7% (fiscal 2023); the current reading is higher than 33% of that period. That is below the Medical Devices industry median of 10.4% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2026 | −1.97% | (5.92) |
| FY2025 | 3.95% | (8.06) |
| FY2024 | 12.0% | (5.66) |
| FY2023 | 17.7% | 3.57 |
| FY2022 | 14.1% | 26.04 |
| FY2021 | −11.9% | (14.10) |
| FY2020 | 2.16% | (4.88) |
| FY2019 | 7.04% | 5.03 |
| FY2018 | 2.01% | 4.51 |
| FY2017 | −2.50% | (2.33) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 9.30% | 3.70 |
| Jun 2026 | 5.60% | 0.84 |
| Mar 2026 | 4.76% | 7.51 |
| Dec 2025 | −2.75% | 2.52 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| AXGN AxoGen, Inc. compare | 24.3% |
| IRTC iRhythm Holdings, Inc. compare | 21.6% |
| LIVN LivaNova PLC compare | 11.7% |
| HAE Haemonetics Corporation | 4.11% |
| BRKR Bruker Corporation compare | 2.16% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 1.38% |
| BIO Bio-Rad Laboratories, Inc. compare | 1.38% |
| ITGR Integer Holdings Corporation compare | −0.31% |
| TXG 10x Genomics compare | −4.28% |
| Medical Devices industry median | 10.4% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on HAE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement